PL446441A1 - 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego - Google Patents

2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego

Info

Publication number
PL446441A1
PL446441A1 PL446441A PL44644123A PL446441A1 PL 446441 A1 PL446441 A1 PL 446441A1 PL 446441 A PL446441 A PL 446441A PL 44644123 A PL44644123 A PL 44644123A PL 446441 A1 PL446441 A1 PL 446441A1
Authority
PL
Poland
Prior art keywords
prevention
treatment
vascular endothelial
diseases associated
phytyl
Prior art date
Application number
PL446441A
Other languages
English (en)
Inventor
Stefan CHŁOPICKI
Szczepan Zapotoczny
Anna KIEROŃSKA-RUDEK
Agnieszka KIJ
Anna BAR
Małgorzata JANIK-HAZUK
Justyna BEDNORZ
Original Assignee
Chde Polska Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chde Polska Spółka Akcyjna filed Critical Chde Polska Spółka Akcyjna
Priority to PL446441A priority Critical patent/PL446441A1/pl
Priority to PCT/PL2024/000056 priority patent/WO2025084940A1/en
Publication of PL446441A1 publication Critical patent/PL446441A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest związek do stosowania w leczeniu chorób lub zapobieganiu chorobom przebiegających z dysfunkcją śródbłonka naczyniowego, przy czym jest on dostarczany w nanokapsułach o średnicy nie większej niż 1 µm, zawierających lipofilowy rdzeń i hydrofilową powłokę, przy czym nanokapsuły przeznaczone są do podawania doustnego.
PL446441A 2023-10-20 2023-10-20 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego PL446441A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL446441A PL446441A1 (pl) 2023-10-20 2023-10-20 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego
PCT/PL2024/000056 WO2025084940A1 (en) 2023-10-20 2024-10-18 2-methyl-3-phytyl-1,4-naphthoquinone for use in the treatment or prevention of diseases with dysfunction of vascular endothelium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL446441A PL446441A1 (pl) 2023-10-20 2023-10-20 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego

Publications (1)

Publication Number Publication Date
PL446441A1 true PL446441A1 (pl) 2025-04-22

Family

ID=93939479

Family Applications (1)

Application Number Title Priority Date Filing Date
PL446441A PL446441A1 (pl) 2023-10-20 2023-10-20 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego

Country Status (2)

Country Link
PL (1) PL446441A1 (pl)
WO (1) WO2025084940A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017014655A1 (en) * 2015-07-17 2017-01-26 Uniwersytet Jagiellonski Nanocapsule for delivery of lipophilic compound and process of preparation thereof
WO2019191773A1 (en) * 2018-03-30 2019-10-03 Kaydence Pharma As Rapidly improving vascular conditions by administering vitamin k

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220182D0 (en) * 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
EP3258924A2 (en) * 2015-02-20 2017-12-27 VitaK B.V. Vitamin k and capillary function
BR112021017994A2 (pt) * 2019-03-11 2021-11-16 Kaydence Pharma As Método para melhorar função cardiovascular, elasticidade, redução de calcificação, pwv e/ou função endotelial, kit, e, composições para uso na melhoria de função cardiovascular, elasticidade, redução de calcificação, pwv e/ou função endotelial, na reversão de calcificação de vasos sanguíneos e no aumento de produção de óxido nítrico endotelial

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017014655A1 (en) * 2015-07-17 2017-01-26 Uniwersytet Jagiellonski Nanocapsule for delivery of lipophilic compound and process of preparation thereof
WO2019191773A1 (en) * 2018-03-30 2019-10-03 Kaydence Pharma As Rapidly improving vascular conditions by administering vitamin k

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIEROŃSKA-RUDEK, ANNA & KIJ, AGNIESZKA & JANIK-HAZUKA, MAŁGORZATA & BEDNORZ, JUSTYNA & ZAPOTOCZNY, SZCZEPAN & CHLOPICKI, STEFAN, (2022). ENDOTHELIUM-TARGETED DELIVERY OF VITAMIN K1 USING HYALURONAN-BASED CAPSULES.; JULY 2022 CONFERENCE: SHAPING MEDICINAL CHEMISTRY FOR THE NEW DECADE AT: ROME, ITALY *

Also Published As

Publication number Publication date
WO2025084940A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
Bumpus Jr Urinary reflux
MA26859A1 (fr) Forme posologique de medicament commandée par un hydrogel.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
CO5150202A1 (es) Composicion de tisu facial y metodo para usarla para el secuestro de irritantes de la piel de la secrecion nasal
HUP9801324A2 (hu) Eljárás és készlet merevedési zavarok megelőzésére
BG104620A (en) Oral pharmaceutical extended release dosage form
KR940006578A (ko) 2-(3,4-디메톡신나모일) 아미노벤조산
Trambert et al. Percutaneous transhepatic balloon dilatation of benign biliary strictures
HUP0303838A2 (hu) Eritropoietin mérsékli a kemoterápia-indukált toxicitást in vivo
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
ATE235901T1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma- butyrobetain für die behandlung von herz-gefäss- erkrankungen
ES2185153T3 (es) Uso de mefloquina(+) para el tratamiento de la malaria.
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
BR0215389A (pt) Agente preventivo ou terapêutico para distúrbio urinário, método para prevenir ou tratar distúrbio urinário, uso de um composto, composto, pró-droga, processo para preparar o composto, medicamento, e, método para triar um composto
Giuliano et al. Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats
Nadalo et al. What is the best way to treat tinea cruris?
ES2192217T3 (es) Sertralina para el tratamiento de pacientes tras un infarto de miocardio.
AR014082A1 (es) Concentrado oral de sertralina
Ryalls et al. A preliminary evaluation of the clinical effectiveness of vowel training for hearing-impaired children on IBM's SpeechViewer
Ludolph et al. Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis?: arguments against
Robinson et al. The incidence of awareness, and amnesia for perioperative events, after cardiac surgery with lorazepam and fentanyl anesthesia
Cherry et al. Upper respiratory tract infections
RU2000110839A (ru) Способ профилактики острого панкреатита после прямых операций на поджелудочной железе
AR031104A1 (es) Composicion farmaceutica que comprende un carboxialquileter y un agente antihipertensivo, primera composicion para su uso con una segunda composicion que comprenden un agente antihipertensivo y un carboxialquileter respectivamente, equipo que comprende un carboxialquileter y un agente antihipertensi